row-start col-sm-8 normal-section border-top-section


NHF’s 71st Bleeding Disorders Conference: Medical Track for Physicians, Researchers, Physician Assistants, Pharmacists and Nurse Practitioners in Bleeding Disorders

October 4-5, 2019 at the Hilton Anaheim in Anaheim, CA
Jointly provided by Postgraduate Institute for Medicine and the National Hemophilia Foundation
Target Audience
This activity is intended for Physicians, Physician Assistants, Researchers, Nurse Practitioners and Pharmacists who are engaged in the care of patients with bleeding disorders in primary care, hospitals and hemophilia treatment centers.
Educational Objectives
After completing this activity, the participant should be better able to: 
  • Review the highlights presented through the MASAC guidance and ICER report findings pertaining to emicizumab
  • Describe practical aspects of transitioning to emicizumab and perioperative considerations
  • Discuss immune tolerance induction approaches as they pertain to emicizumab
  • Review the latest outcomes in gene therapy clinical trials for hemophilia B
  • Discuss the potential advantages and challenges to the future use of gene therapy for hemophilia treatment
  • Describe cardiovascular risk factors and morbidity for patients with inherited bleeding disorders compared to the general population
  • Identify the risk-benefit in use of anti-platelet or anti-coagulant therapies for individuals with cardiovascular disease and an inherited bleeding disorder
  • Explain emerging scientific advances that might improve diagnosis and treatment of patients with rare bleeding disorders
  • Identify 2 investigator-initiated research projects in bleeding disorders being funded through the National Hemophilia Foundation
Meera Chitlur, MD
Children’s Hospital of Michigan  
Detroit, MI  
Steven W. Pipe, MD
University of Michigan
Ann Arbor, MI
Stacy Croteau, MD, MMS
Boston Hemophilia Center
Boston, MA
Christopher Walsh, MD, PhD
Mount Sinai Hospital - HTC
New York, NY
Medical Track Program Agenda
Friday, October 4, 2019
  • 9:15 am - 12:15 pm
    • New and Expanding Clinical Guidance on Management of Hemophilia A with Emicizumab *CME/ACPE
  • 12:30 pm - 1:30 pm
    • Physician/Researcher's Luncheon
  • 2:00 pm - 5:00 pm 
    • The Road Ahead - Updates in Gene Therapy Clinical Trials for Hemophilia B *CME/ACPE 
  • 5:30 pm - 6:30 pm
    • Research Posters Reception
Saturday, October 5, 2019
  • 9:15 am - 12:00 pm
    • Managing Cardiovascular Health: Challenges with Risk Assessment and Balance of Therapeutic Needs in Hemophilia Patients *CME/ACPE
  • 1:45 pm - 4:00 pm
    • Presentations from NHF's Funded Researchers and Investigators *CME/ACPE
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Hemophilia Foundation. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 10.5 contact hours (1.05 CEUs) of the Accreditation Council for Pharmacy Education.

The ACPE Universal Activity Number is: JA4008162-9999-19-762-L01-P
Type of Activity: Knowledge

This activity is supported, in part, by independent educational grants (currently pending). 
Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Americans with Disabilities Act  
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact Alla Vaynshteyn, NHF Manager of Conference & Travel Services, prior to this live event at
Fee Information  
There are no additional fees charged for this educational activity. All eligible healthcare providers who register at ‘full’ provider level (ie. physician, researcher, nurse, pharmacist, physical therapist, social worker) will be able to obtain CME/CE credits for specific provider track sessions at NHF’s 71st Bleeding Disorders Conference. Any attendee interested in CME/CE without a full provider (or full industry/full exhibitor) badge will need to visit the NHF 71st Bleeding Disorders Conference registration desk located in the Anaheim Convention Center to upgrade their registration.

To access NHF’s 70th Bleeding Disorders Conference main webpage with more details on conference registration, a breakdown of fees by attendee category, or to view NHF’s 2019 cancellation policy, click here.

Additionally, all providers interested in CME/CE will need to visit NHF’s “CME/CE Desk” at the Anaheim Hilton to first sign-in and obtain a program handout with instructions for obtaining CME/CE credit. (Please refer to NHF’s Onsite Conference book for information on the location of NHF’s onsite CME/CE Desk and its hours of operation).

Attending the NHF BD Conference alone is not enough to warrant attainment of credit. For any additional questions about provider education at NHF’s 71st Bleeding Disorders Conference, please check the NHF website for updates or contact Angelina Wang, NHF Director of Medical Programs and Information at
row-mid col-sm-4 top-overlap no-pad
row-mid col-sm-4 border-top margin-top

Share This Event

row-mid margin-top col-sm-4